- AbbVie Inc ABBV has submitted marketing applications to the FDA and European Medicines Agency (EMA) seeking approval for Skyrizi (risankizumab-rzaa, 150 mg) for the treatment of adults with active psoriatic arthritis.
- In the Phase 3 KEEPsAKE-1 and KEEPsAKE-2 studies, Skyrizi demonstrated significant improvements in disease activity, skin clearance, and physical function at week 24 versus placebo.
- Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.
- Price Action: ABBV shares were down 0.28% at $105.09 during market trading hours on the last check Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
